Ocular Therapeutix (OCUL) Tops Q3 EPS by 2c

Ocular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.22), $0.02 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $15.42 million versus the consensus estimate of $17.13 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Bernstein SocGen Group Downgrades Bridgestone Corp. (5108:JP) (BRDCY) to Market Perform
• Increasing unusual put volume: OCUL IRM ALOY DFTX WY CIA ATAI WGMI ROST SLS EQX CRWG MUU CAVA BURL D NBIG ZSL